Cargando…
Outcomes of autologous bone marrow mononuclear cell administration in the treatment of neurologic sequelae in children with spina bifida
BACKGROUND: To evaluate the safety and efficacy of autologous bone marrow mononuclear cell (BMMNC) infusion in the management of neurological sequelae in children with spina bifida (SB). METHODS: BMMNCs were harvested from bilateral anterior iliac crests. Two intrathecal BMMNC administrations were p...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148418/ https://www.ncbi.nlm.nih.gov/pubmed/37118832 http://dx.doi.org/10.1186/s13287-023-03349-w |
_version_ | 1785034970994049024 |
---|---|
author | Nguyen, Liem Thanh Le, Huong Thu Nguyen, Kien Trung Bui, Hang Thi Nguyen, Anh Phuong Thi Ngo, Doan Van Hoang, Duc Minh Ngo, Minh Duy |
author_facet | Nguyen, Liem Thanh Le, Huong Thu Nguyen, Kien Trung Bui, Hang Thi Nguyen, Anh Phuong Thi Ngo, Doan Van Hoang, Duc Minh Ngo, Minh Duy |
author_sort | Nguyen, Liem Thanh |
collection | PubMed |
description | BACKGROUND: To evaluate the safety and efficacy of autologous bone marrow mononuclear cell (BMMNC) infusion in the management of neurological sequelae in children with spina bifida (SB). METHODS: BMMNCs were harvested from bilateral anterior iliac crests. Two intrathecal BMMNC administrations were performed with an interval of 6 months. The measurements of outcomes included clinical assessments, cystomanometry and rectomanometry. RESULTS: Eleven children with SB underwent autologous BMMNC infusions from 2016 to 2020. There were no severe adverse events during the study period. The number of patients requiring assistance to expel stools decreased from 11 before cell infusion to 3 after the second cell infusion. The number of patients who had urine leakage decreased from 9 patients at baseline to 3 patients after the second BMMNC infusion. The mean bladder capacity increased from 127.7 ± 59.2 ml at baseline to 136.3 ± 54.8 ml at six months and to 158.3 ± 56.2 ml at 12 months after BMMNC infusions. Detrusor pressure (pdet) decreased from 32.4 ± 22.0 cm H(2)O at baseline to 21.9 ± 11.8 cm H(2)O after 12 months of follow-up. At baseline, six patients could walk independently. After the 2nd infusion, eight patients could walk independently. CONCLUSION: Intrathecal infusions of autologous bone marrow mononuclear cells are safe and may improve bowel, bladder, and motor function in children with SB. Trial registration: NCT, NCT05472428. Registered July 25, 2022- Retrospectively registered, https://www.clinicaltrials.gov/ct2/show/NCT05472428. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13287-023-03349-w. |
format | Online Article Text |
id | pubmed-10148418 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-101484182023-04-30 Outcomes of autologous bone marrow mononuclear cell administration in the treatment of neurologic sequelae in children with spina bifida Nguyen, Liem Thanh Le, Huong Thu Nguyen, Kien Trung Bui, Hang Thi Nguyen, Anh Phuong Thi Ngo, Doan Van Hoang, Duc Minh Ngo, Minh Duy Stem Cell Res Ther Research BACKGROUND: To evaluate the safety and efficacy of autologous bone marrow mononuclear cell (BMMNC) infusion in the management of neurological sequelae in children with spina bifida (SB). METHODS: BMMNCs were harvested from bilateral anterior iliac crests. Two intrathecal BMMNC administrations were performed with an interval of 6 months. The measurements of outcomes included clinical assessments, cystomanometry and rectomanometry. RESULTS: Eleven children with SB underwent autologous BMMNC infusions from 2016 to 2020. There were no severe adverse events during the study period. The number of patients requiring assistance to expel stools decreased from 11 before cell infusion to 3 after the second cell infusion. The number of patients who had urine leakage decreased from 9 patients at baseline to 3 patients after the second BMMNC infusion. The mean bladder capacity increased from 127.7 ± 59.2 ml at baseline to 136.3 ± 54.8 ml at six months and to 158.3 ± 56.2 ml at 12 months after BMMNC infusions. Detrusor pressure (pdet) decreased from 32.4 ± 22.0 cm H(2)O at baseline to 21.9 ± 11.8 cm H(2)O after 12 months of follow-up. At baseline, six patients could walk independently. After the 2nd infusion, eight patients could walk independently. CONCLUSION: Intrathecal infusions of autologous bone marrow mononuclear cells are safe and may improve bowel, bladder, and motor function in children with SB. Trial registration: NCT, NCT05472428. Registered July 25, 2022- Retrospectively registered, https://www.clinicaltrials.gov/ct2/show/NCT05472428. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13287-023-03349-w. BioMed Central 2023-04-28 /pmc/articles/PMC10148418/ /pubmed/37118832 http://dx.doi.org/10.1186/s13287-023-03349-w Text en © The Author(s) 2023, Corrected publication. May 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Nguyen, Liem Thanh Le, Huong Thu Nguyen, Kien Trung Bui, Hang Thi Nguyen, Anh Phuong Thi Ngo, Doan Van Hoang, Duc Minh Ngo, Minh Duy Outcomes of autologous bone marrow mononuclear cell administration in the treatment of neurologic sequelae in children with spina bifida |
title | Outcomes of autologous bone marrow mononuclear cell administration in the treatment of neurologic sequelae in children with spina bifida |
title_full | Outcomes of autologous bone marrow mononuclear cell administration in the treatment of neurologic sequelae in children with spina bifida |
title_fullStr | Outcomes of autologous bone marrow mononuclear cell administration in the treatment of neurologic sequelae in children with spina bifida |
title_full_unstemmed | Outcomes of autologous bone marrow mononuclear cell administration in the treatment of neurologic sequelae in children with spina bifida |
title_short | Outcomes of autologous bone marrow mononuclear cell administration in the treatment of neurologic sequelae in children with spina bifida |
title_sort | outcomes of autologous bone marrow mononuclear cell administration in the treatment of neurologic sequelae in children with spina bifida |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148418/ https://www.ncbi.nlm.nih.gov/pubmed/37118832 http://dx.doi.org/10.1186/s13287-023-03349-w |
work_keys_str_mv | AT nguyenliemthanh outcomesofautologousbonemarrowmononuclearcelladministrationinthetreatmentofneurologicsequelaeinchildrenwithspinabifida AT lehuongthu outcomesofautologousbonemarrowmononuclearcelladministrationinthetreatmentofneurologicsequelaeinchildrenwithspinabifida AT nguyenkientrung outcomesofautologousbonemarrowmononuclearcelladministrationinthetreatmentofneurologicsequelaeinchildrenwithspinabifida AT buihangthi outcomesofautologousbonemarrowmononuclearcelladministrationinthetreatmentofneurologicsequelaeinchildrenwithspinabifida AT nguyenanhphuongthi outcomesofautologousbonemarrowmononuclearcelladministrationinthetreatmentofneurologicsequelaeinchildrenwithspinabifida AT ngodoanvan outcomesofautologousbonemarrowmononuclearcelladministrationinthetreatmentofneurologicsequelaeinchildrenwithspinabifida AT hoangducminh outcomesofautologousbonemarrowmononuclearcelladministrationinthetreatmentofneurologicsequelaeinchildrenwithspinabifida AT ngominhduy outcomesofautologousbonemarrowmononuclearcelladministrationinthetreatmentofneurologicsequelaeinchildrenwithspinabifida |